VAKCINA

lalinea wrote:kinezi su skroz druga prica sa svojom drzavnom vakcinom i milijardu ipo volontera... oni mogu da vakcinisu par stotina hiljada dece, zakljuce da je vakcina bezbedna, a koliko je efikasna - to je manje bitno. ove kapitalisticke kompanije ipak gledaju da ne trose resurse na trials koja nemaju sansu da im daju dovoljno podataka da prodju pravila za odobravanje raznih zapadnih drzava.

Marius Lăcătuș wrote:kako misliš da im je manje bitno koliko je efikasna?

ko ce kupiti neefikasnu vakcinu u prodaji?

Talason wrote:

lalinea wrote:kinezi su skroz druga prica sa svojom drzavnom vakcinom i milijardu ipo volontera... oni mogu da vakcinisu par stotina hiljada dece, zakljuce da je vakcina bezbedna, a koliko je efikasna - to je manje bitno. ove kapitalisticke kompanije ipak gledaju da ne trose resurse na trials koja nemaju sansu da im daju dovoljno podataka da prodju pravila za odobravanje raznih zapadnih drzava.

pa samo je bezbednost važna, efikasnost ne mogu da procene, ne završavaju deca na respiratorima

lalinea wrote:

Marius Lăcătuș wrote:kako misliš da im je manje bitno koliko je efikasna?

ko ce kupiti neefikasnu vakcinu u prodaji?

ne mislim 'potpuno neefikasna', vec da ne mogu pouzdano da dokazu da zadovoljava procente potrebne za odobravanje.  

Marius Lăcătuș wrote:

lalinea wrote:
ne mislim 'potpuno neefikasna', vec da ne mogu pouzdano da dokazu da zadovoljava procente potrebne za odobravanje.  

Kako je pfizer pOUzdaNo dokazao zadovoljavajuce procente

Marius Lăcătuș wrote:pfizer je pre izraela mogao samo da ima neku statisticku simulaciju koja se u nedostatku realnog dokaza ono sto se (u kapitalizmu) prihvata da bi se odobrila upotreba, pod uslovom da je kriterijum bezbednosti zadovoljen..

Marius Lăcătuș wrote:Koliko su "dovoljno velike"?

Ništa od toga nije važnije od stvarne prakse na milionima ljudi, a posebno na stvarnim sojevima koji danas napadaju ljude. Najbolje da će da bude relevantna peer reviewed analiza na soju čije se broj zaraženih pribiližava jednocifrenim procentima.

Razumem zašto ljudi koji se bave naukom brane i štite naučne modele - ovde je za mene jedini problem što danas to nije jedini meritum koji ima uticaja na prihvaćenost i mišljenje o nekoj vakcini, koja izlaskom na slobodno tržište prestaje da bude samo naučni domen. Drugim rečima, kineska vacKina nikada na zapadnom tržištu neće imati tretman koji imaju Pfizer, Oxford i Moderna.

Lično me zabole, a i ne znam zašto pišem ovo.

COVAX sets out plan for global distribution of 337m vaccines https://t.co/XkDyKRSxo7 pic.twitter.com/Re0WbImDFF

— Al Jazeera News (@AJENews) February 3, 2021

We just announced that the Swiss Federal Government has increased its confirmed order commitment from 7.5 million to 13.5 million doses of the COVID-19 Vaccine Moderna in Switzerland. https://t.co/g5HzTezo2c pic.twitter.com/lSY4icackW

— Moderna (@moderna_tx) February 3, 2021

rumbeando wrote:

COVAX sets out plan for global distribution of 337m vaccines https://t.co/XkDyKRSxo7 pic.twitter.com/Re0WbImDFF

— Al Jazeera News (@AJENews) February 3, 2021

Deli se 240 miliona doza oksfordske vakcine proizvedene u Indiji, 96 miliona doza oksfordske proizvedene van Indije i 1,2 miliona doza Fajzera.

Srbija dobija 345.600 oksfordskih vakcina koje nisu proizvedene u Indiji.
https://www.who.int/docs/default-source/coronaviruse/act-accelerator/covax/covax-interim-distribution-forecast.pdf?sfvrsn=7889475d_5

Rolling authorisation application for COVID-19 vaccines Swissmedic requests additional data
Swissmedic examines the data on the vaccine from AstraZeneca it receives on an ongoing basis
03.02.2021
Swissmedic is currently reviewing two applications for the authorisation of COVID-19 vaccines. With regard to the AstraZeneca vaccine, the data submitted and analysed so far are not yet sufficient to permit authorisation. To obtain more information about safety, efficacy and quality, additional data from new studies are needed.
Swissmedic is currently reviewing two applications for the authorisation of COVID-19 vaccines in the rolling review procedure, including the application for the authorisation of the “COVID-19 Vaccine AstraZeneca” (AZD1222) for the coronavirus. At an extraordinary meeting on 2 February 2021, the external Swissmedic advisory body HMEC (Human Medicines Expert Committee) confirmed Swissmedic’s interim assessment of the AstraZeneca coronavirus vaccine based on the data analysed to date. The data currently available do not point to a positive decision regarding benefits and risks.
To obtain a conclusive assessment, the applicant will among other things have to submit additional efficacy data from a Phase III trial under way in North and South America, and these will have to be analysed. As soon as the results have been received, a temporary authorisation according to the rolling procedure could be issued at very short notice.

Mór Thököly wrote:Doza ili vakcina.

This document contains information on indicative distribution of 240 million doses of the AstraZeneca/Oxford vaccine, licensed to Serum Institute of India (SII) – hereinafter “AZ/SII” and 96 million doses of the AstraZeneca/Oxford vaccine, under the advance purchase agreement between Gavi, the Vaccine Alliance and AstraZeneca – hereinafter “AZ”, for Q1 & Q2 2021. It also contains an overview of exceptional first round allocation of 1.2 million doses of the WHO Emergency Use Listing (EUL)-approved Pfizer-BioNTech vaccine – hereinafter “Pfizer-BioNTech”, for Q1 2021.